| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 5 |
| 1 | ATEZOLIZUMAB | 4 |
| 2 | CARBOPLATIN | 4 |
| 3 | ETOPOSIDE | 4 |
| 4 | BEVACIZUMAB | 3 |
| 5 | DEXAMETHASONE | 3 |
| 6 | DEXAMETHASONE 1.5 MG | 3 |
| 7 | NIVOLUMAB | 3 |
| 8 | CYCLOPHOSPHAMIDE | 2 |
| 9 | CYCLOPHOSPHAMIDE FOR INJECTION | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LIFILEUCEL | 1 | 0.0035 |
| 1 | PHENAZOPYRIDINE | 1 | 0.0003 |
| 2 | FOSCARNET SODIUM | 1 | 0.0002 |
| 3 | PENTOSAN POLYSULFATE SODIUM | 1 | 0.0001 |
| 4 | ATEZOLIZUMAB | 4 | 0.0001 |
| 5 | GANCICLOVIR SODIUM | 1 | 0.0001 |
| 6 | VEMURAFENIB | 1 | 0.0001 |
| 7 | ETOPOSIDE | 4 | 0.0001 |
| 8 | NIFEDIPINE | 2 | 0.0000 |
| 9 | DABRAFENIB | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 12 | 0.0001 |
| 1 | Topoisomerase Inhibitor [EPC] | 4 | 0.0001 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 3 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 2 | 0.0000 |
| 5 | Estrogen Receptor Antagonist [EPC] | 1 | 0.0000 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 3 | 0.0000 |
| 7 | Platinum-based Drug [EPC] | 4 | 0.0000 |
| 8 | Nucleoside Analog Antiviral [EPC] | 1 | 0.0000 |
| 9 | Proteasome Inhibitor [EPC] | 1 | 0.0000 |